Zhejiang Doer Biologics unveils first-in-class tri-agonist for high lipidsnews2025-11-14T17:56:23+00:00November 14th, 2025|Endpoints News|
Bristol Myers, J&J’s next-gen blood thinner fails key trial in another setback for factor XInews2025-11-14T16:16:30+00:00November 14th, 2025|Endpoints News|
Pfizer reduces stake in BioNTech; Candel pauses pancreatic cancer programnews2025-11-14T16:06:15+00:00November 14th, 2025|Endpoints News|
Cartesian to pause work in form of lupus, despite trial successnews2025-11-14T15:48:11+00:00November 14th, 2025|Endpoints News|
Exclusive: The inside story of Pfizer and Novo’s fight for the $10B Metsera dealnews2025-11-14T14:00:19+00:00November 14th, 2025|Endpoints News|
Lundbeck fires the first shot in a bidding war with Alkermes over sleep biotech Avadelnews2025-11-14T12:10:08+00:00November 14th, 2025|Endpoints News|
Merck to buy Cidara and its preventive influenza biologic for $9.2Bnews2025-11-14T12:09:54+00:00November 14th, 2025|Endpoints News|
Mikael Dolsten removes himself from board candidacy at Novo; Bavarian Nordic chairman resignsnews2025-11-14T12:00:22+00:00November 14th, 2025|Endpoints News|
Medicxi, which backed Vicebio and Versanis, closes new €500M biotech fundnews2025-11-14T11:57:42+00:00November 14th, 2025|Endpoints News|
FDA approves Kura and Kyowa Kirin’s drug for form of acute myeloid leukemianews2025-11-13T19:58:31+00:00November 13th, 2025|Endpoints News|
